CDC42EP3

Summary

CDC42EP3 (CDC42 effector protein 3, HGNC:16943) is a protein-coding gene on chromosome 2p22.2, encoding Cdc42 effector protein 3 (Q9UKI2). Probably involved in the organization of the actin cytoskeleton.

This gene encodes a member of a small family of guanosine triphosphate (GTP) metabolizing proteins that contain a CRIB (Cdc42, Rac interactive binding) domain. Members of this family of proteins act as effectors of CDC42 function. The encoded protein is involved in actin cytoskeleton re-organization during cell shape changes, including pseudopodia formation. A pseudogene of this gene is found on chromosome 19. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 10602 — RefSeq curated summary.

At a glance

• GWAS associations: 21
• Clinical variants (ClinVar): 49 total
• MANE Select transcript: NM_006449

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16943
Approved symbol	CDC42EP3
Name	CDC42 effector protein 3
Location	2p22.2
Locus type	gene with protein product
Status	Approved
Aliases	CEP3, UB1, BORG2
Ensembl gene	ENSG00000163171
Ensembl biotype	protein_coding
OMIM	606133
Entrez	10602

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 24 protein_coding, 1 retained_intron

ENST00000295324, ENST00000422687, ENST00000453555, ENST00000457889, ENST00000494083, ENST00000611976, ENST00000885380, ENST00000885381, ENST00000885382, ENST00000885383, ENST00000885384, ENST00000927367, ENST00000927368, ENST00000927369, ENST00000927370, ENST00000927371, ENST00000956783, ENST00000956784, ENST00000956785, ENST00000956786, ENST00000956787, ENST00000956788, ENST00000956789, ENST00000956790, ENST00000956791

RefSeq mRNA: 6 — MANE Select: NM_006449 NM_001270436, NM_001270437, NM_001270438, NM_001371569, NM_001371570, NM_006449

CCDS: CCDS1791

Canonical transcript exons

ENST00000295324 — 2 exons

Exon	Start	End
ENSE00001072281	37641944	37646822
ENSE00001369735	37671426	37671642

Expression profiles

Bgee: expression breadth ubiquitous, 284 present calls, max score 97.86.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 115.5665 / max 2412.6846, expressed in 1752 samples.

FANTOM5 promoters (13 alternative TSS)

Promoter ID	TPM avg	Samples expressed
27822	100.1697	1739
27823	8.3194	1532
27810	1.7992	769
27827	1.4721	860
27825	1.3741	744
27816	1.0561	575
27824	0.5133	296
27826	0.3436	181
27813	0.1736	61
27814	0.1618	53

Top tissues by expression

299 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tibia	UBERON:0000979	97.86	gold quality
monocyte	CL:0000576	97.69	gold quality
seminal vesicle	UBERON:0000998	97.62	gold quality
mononuclear cell	CL:0000842	97.50	gold quality
left ventricle myocardium	UBERON:0006566	97.49	gold quality
renal glomerulus	UBERON:0000074	97.39	gold quality
leukocyte	CL:0000738	97.37	gold quality
metanephric glomerulus	UBERON:0004736	97.08	gold quality
saphenous vein	UBERON:0007318	97.06	gold quality
heart right ventricle	UBERON:0002080	96.57	gold quality
cauda epididymis	UBERON:0004360	96.50	gold quality
myometrium	UBERON:0001296	96.26	gold quality
myocardium	UBERON:0002349	96.15	gold quality
blood	UBERON:0000178	95.92	gold quality
smooth muscle tissue	UBERON:0001135	95.86	gold quality
cardiac muscle of right atrium	UBERON:0003379	95.23	gold quality
decidua	UBERON:0002450	95.11	gold quality
adult organism	UBERON:0007023	95.07	gold quality
cartilage tissue	UBERON:0002418	94.95	gold quality
mucosa of paranasal sinus	UBERON:0005030	94.82	gold quality
urethra	UBERON:0000057	94.71	gold quality
body of uterus	UBERON:0009853	94.62	gold quality
pericardium	UBERON:0002407	94.61	gold quality
ganglionic eminence	UBERON:0004023	94.61	gold quality
granulocyte	CL:0000094	94.22	gold quality
tibialis anterior	UBERON:0001385	94.20	gold quality
buccal mucosa cell	CL:0002336	94.11	gold quality
vena cava	UBERON:0004087	94.06	gold quality
choroid plexus epithelium	UBERON:0003911	93.94	gold quality
blood vessel layer	UBERON:0004797	93.89	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-MTAB-8142	yes	1454.67
E-MTAB-10287	yes	42.22
E-MTAB-9221	yes	23.25
E-CURD-112	yes	8.60
E-GEOD-135922	yes	6.79
E-CURD-46	yes	5.10
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

129 targeting CDC42EP3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4692	100.00	67.32	2066
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-545-3P	99.95	70.74	2783

Literature-anchored findings (GeneRIF, showing 7)

• The expression of CDC42EP3 mRNA was significantly increased by 19.7% in dorsal prefrontal cortex in patient with schizophrenia. (PMID:20385374)
• Results provide evidence that Cdc42EP3 function in cancer-associated fibroblasts relies on tight regulation by Cdc42. (PMID:27248291)
• Studies indicate some of the functional and mechanistic roles of the binder of Rho GTPases Borg1-5 proteins (Cdc42EP1-5), including cytoskeletal remodelling and signalling. (PMID:27913681)
• Overactivated Cdc42 acts through Cdc42EP3/Borg2 and NCK to trigger DNA damage response signaling and sensitize cells to DNA-damaging agents. (PMID:32739212)
• CDC42EP3 is a key promoter involved in the development and progression of gastric cancer. (PMID:34111280)
• Deduction of CDC42EP3 suppress development and progression of osteosarcoma. (PMID:34998812)
• CDC42EP3 promotes glioma progression via regulation of CCND1. (PMID:35365622)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cdc42ep3	ENSDARG00000052783
mus_musculus	Cdc42ep3	ENSMUSG00000036533
rattus_norvegicus	Cdc42ep3	ENSRNOG00000032136

Paralogs (5): CDC42EP1 (ENSG00000128283), CDC42EP2 (ENSG00000149798), CDC42EP5 (ENSG00000167617), CDC42EP4 (ENSG00000179604), C15orf62 (ENSG00000188277)

Protein

Protein identifiers

Cdc42 effector protein 3 — Q9UKI2 (reviewed: Q9UKI2)

Alternative names: Binder of Rho GTPases 2, MSE55-related Cdc42-binding protein

All UniProt accessions (4): Q9UKI2, C9J7F7, C9JEZ4, C9JKW5

UniProt curated annotations — full annotation on UniProt →

Function. Probably involved in the organization of the actin cytoskeleton. May act downstream of CDC42 to induce actin filament assembly leading to cell shape changes. Induces pseudopodia formation in fibroblasts.

Subunit / interactions. Interacts with RHOQ and CDC42, in a GTP-dependent manner, and with SEPT7.

Subcellular location. Endomembrane system. Cytoplasm. Cytoskeleton.

Tissue specificity. Highly expressed in the heart and weakly in the brain.

Similarity. Belongs to the BORG/CEP family.

RefSeq proteins (6): NP_001257365, NP_001257366, NP_001257367, NP_001358498, NP_001358499, NP_006440* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000095	CRIB_dom	Domain
IPR029273	Cdc42_effect-like	Domain
IPR051296	Cdc42_Effector_BORG/CEP	Family

Pfam: PF00786, PF14957

UniProt features (10 total): modified residue 4, sequence conflict 2, chain 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UKI2-F1	58.43	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 63, 89, 108, 144

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-5687128	MAPK6/MAPK4 signaling
R-HSA-9013148	CDC42 GTPase cycle
R-HSA-9013406	RHOQ GTPase cycle
R-HSA-162582	Signal Transduction
R-HSA-194315	Signaling by Rho GTPases
R-HSA-5683057	MAPK family signaling cascades
R-HSA-9012999	RHO GTPase cycle
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3

MSigDB gene sets: 435 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_UP, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, HNF3ALPHA_Q6, GOBP_REGULATION_OF_CELL_MORPHOGENESIS, GCANCTGNY_MYOD_Q6, CHUNG_BLISTER_CYTOTOXICITY_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, IVANOVA_HEMATOPOIESIS_MATURE_CELL, TGACCTY_ERR1_Q2, GOMF_GTPASE_BINDING, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, NAGASHIMA_NRG1_SIGNALING_UP, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS

GO Biological Process (5): signal transduction (GO:0007165), Rho protein signal transduction (GO:0007266), regulation of cell shape (GO:0008360), positive regulation of actin filament polymerization (GO:0030838), positive regulation of pseudopodium assembly (GO:0031274)

GO Molecular Function (3): cytoskeletal regulatory protein binding (GO:0005519), small GTPase binding (GO:0031267), protein binding (GO:0005515)

GO Cellular Component (7): cytoplasm (GO:0005737), cytosol (GO:0005829), cytoskeleton (GO:0005856), plasma membrane (GO:0005886), endomembrane system (GO:0012505), actin cytoskeleton (GO:0015629), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
RHO GTPase cycle	2
Signal Transduction	2
MAPK family signaling cascades	1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
Signaling by Rho GTPases	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
small GTPase-mediated signal transduction	1
regulation of cell morphogenesis	1
regulation of biological quality	1
actin filament polymerization	1
regulation of actin filament polymerization	1
positive regulation of protein polymerization	1
positive regulation of cytoskeleton organization	1
positive regulation of supramolecular fiber organization	1
pseudopodium assembly	1
regulation of pseudopodium assembly	1
positive regulation of plasma membrane bounded cell projection assembly	1
cytoskeletal protein binding	1
GTPase binding	1
binding	1
intracellular anatomical structure	1
cytoplasm	1
intracellular membraneless organelle	1
membrane	1
cell periphery	1
vacuole	1
plasma membrane	1
cytoskeleton	1

Protein interactions and networks

STRING

750 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDC42EP3	SKP1	P34991	977
CDC42EP3	CDC42EP5	Q6NZY7	955
CDC42EP3	RHOQ	P17081	954
CDC42EP3	CDC42	P21181	724
CDC42EP3	SEPTIN7	Q16181	662
CDC42EP3	PLIN2	Q99541	543
CDC42EP3	ISG15	P05161	532
CDC42EP3	SEPTIN9	Q9UHD8	522
CDC42EP3	NPLOC4	Q8TAT6	479
CDC42EP3	CEBPZ	Q03701	476
CDC42EP3	TMEM51	Q9NW97	471
CDC42EP3	TP53	P04637	467
CDC42EP3	PUM2	Q8TB72	443
CDC42EP3	ZUP1	Q96AP4	419
CDC42EP3	UBB	P02248	419

IntAct

15 interactions, top by confidence:

A	B	Type	Score
CDC42EP3	LRRK2	psi-mi:“MI:0407”(direct interaction)	0.620
LRRK2	CDC42EP3	psi-mi:“MI:0407”(direct interaction)	0.620
COPE	CDC42EP3	psi-mi:“MI:0915”(physical association)	0.560
CDC42EP3	DAPK1	psi-mi:“MI:0407”(direct interaction)	0.440
CDC42EP3	MFHAS1	psi-mi:“MI:0407”(direct interaction)	0.440
CDC42EP3	SRPK1	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
CDC42EP3	LRRK1	psi-mi:“MI:0407”(direct interaction)	0.440
CDC42EP3	MON1B	psi-mi:“MI:0915”(physical association)	0.400
CDC42EP3	CDC42EP3	psi-mi:“MI:0915”(physical association)	0.370
COPE	CDC42EP3	psi-mi:“MI:0915”(physical association)	0.000
ftsS	CDC42EP3	psi-mi:“MI:0915”(physical association)	0.000
CDC42	CDC42EP3	psi-mi:“MI:0915”(physical association)	0.000
UMPS	CDC42EP3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (32): CDC42EP3 (Two-hybrid), CDC42EP3 (Affinity Capture-RNA), CDC42EP3 (Reconstituted Complex), CDC42EP3 (Reconstituted Complex), CDC42EP3 (Reconstituted Complex), CDC42EP3 (Reconstituted Complex), CDC42EP3 (Two-hybrid), CDC42EP3 (Two-hybrid), CDC42EP3 (Two-hybrid), SEPT7 (Reconstituted Complex), SEPT6 (Reconstituted Complex), CDC42EP3 (Reconstituted Complex), MON1B (Affinity Capture-MS), RHOQ (Reconstituted Complex), CDC42 (Reconstituted Complex)

ESM2 similar proteins: A0A140LFM6, A0A1B0GUA6, A0JMD2, A4IGV6, A6H5Y1, A6NFA0, A6NKB5, A8E653, B3DHS1, D3ZJ47, D3ZMK9, E9Q309, O14513, O60284, P0CAX8, Q1RMQ5, Q32LN6, Q3URK1, Q3UTJ2, Q3ZBS1, Q49A88, Q5DU28, Q5RDK8, Q5REU9, Q5SW75, Q5VT06, Q60664, Q62417, Q642A3, Q68D20, Q6A065, Q6DFB0, Q6NRK3, Q6NWJ0, Q6ZVD7, Q76I79, Q7TSH4, Q8K2J4, Q8K3V7, Q8VEB3

Diamond homologs: A1A5P0, Q00587, Q08DN6, Q17QW1, Q5PQP4, Q6NZY7, Q8JZX9, Q91W92, Q9CQC5, Q9H3Q1, Q9I7F7, Q9JM96, Q9UKI2, Q9Z0X0, O14613

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

49 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	43
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

670 predictions. Top by Δscore:

Variant	Effect	Δscore
2:37645829:A:AC	donor_gain	0.9900
2:37645830:T:C	donor_gain	0.9900
2:37661746:A:C	acceptor_gain	0.9900
2:37661748:G:C	acceptor_gain	0.9900
2:37672088:G:C	donor_gain	0.9900
2:37645789:CCTT:C	donor_gain	0.9800
2:37646819:AAACC:A	acceptor_loss	0.9800
2:37646820:AACCT:A	acceptor_loss	0.9800
2:37646822:CCTG:C	acceptor_loss	0.9800
2:37646823:C:T	acceptor_loss	0.9800
2:37646824:T:A	acceptor_loss	0.9800
2:37661746:A:AC	acceptor_gain	0.9800
2:37645825:A:AC	donor_gain	0.9700
2:37645826:C:CC	donor_gain	0.9700
2:37646818:CAAAC:C	acceptor_gain	0.9700
2:37672239:C:A	donor_gain	0.9700
2:37661750:A:C	acceptor_gain	0.9600
2:37645934:A:AC	donor_gain	0.9500
2:37646823:C:CC	acceptor_gain	0.9500
2:37661748:G:GC	acceptor_gain	0.9500
2:37672280:C:CA	donor_gain	0.9500
2:37645941:C:A	donor_gain	0.9400
2:37672399:G:A	donor_gain	0.9400
2:37645934:AGT:A	donor_gain	0.9200
2:37645940:T:A	donor_gain	0.9100
2:37645935:G:C	donor_gain	0.9000
2:37645900:A:AT	donor_gain	0.8900
2:37671422:TCACC:T	donor_loss	0.8900
2:37671424:A:AA	donor_loss	0.8900
2:37671425:C:G	donor_loss	0.8900

AlphaMissense

1676 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:37646461:G:C	H43D	1.000
2:37646492:A:C	S32R	1.000
2:37646492:A:T	S32R	1.000
2:37646494:T:G	S32R	1.000
2:37646496:A:C	I31S	1.000
2:37646496:A:T	I31N	1.000
2:37646414:A:C	F58L	0.999
2:37646414:A:T	F58L	0.999
2:37646415:A:G	F58S	0.999
2:37646416:A:G	F58L	0.999
2:37646427:C:A	G54V	0.999
2:37646427:C:T	G54E	0.999
2:37646428:C:G	G54R	0.999
2:37646428:C:T	G54R	0.999
2:37646429:A:C	F53L	0.999
2:37646429:A:T	F53L	0.999
2:37646431:A:G	F53L	0.999
2:37646459:G:C	H43Q	0.999
2:37646459:G:T	H43Q	0.999
2:37646460:T:C	H43R	0.999
2:37646468:G:C	H40Q	0.999
2:37646468:G:T	H40Q	0.999
2:37646469:T:C	H40R	0.999
2:37646470:G:C	H40D	0.999
2:37646472:C:G	R39P	0.999
2:37646475:A:G	F38S	0.999
2:37646496:A:G	I31T	0.999
2:37646511:A:T	L26Q	0.999
2:37645848:A:G	L247P	0.998
2:37645873:C:G	G239R	0.998

dbSNP variants (sampled 300 via entrez): RS1000034337 (2:37656820 C>G), RS1000057369 (2:37658888 C>A,G,T), RS1000180105 (2:37663706 G>A), RS1000232460 (2:37663858 C>T), RS1000357113 (2:37668804 G>C), RS1000382904 (2:37674476 C>T), RS1000425580 (2:37674751 G>T), RS1000519326 (2:37662699 A>G), RS1000573118 (2:37662937 G>A), RS1000715474 (2:37673017 A>G), RS1000758365 (2:37671373 GACAGAC>G), RS1000768093 (2:37673308 C>T), RS1001109106 (2:37660543 C>A,T), RS1001152568 (2:37648610 G>A,C), RS1001254147 (2:37674696 A>C)

Disease associations

OMIM: gene MIM:606133 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

21 associations (top):

Study	Trait	p-value
GCST000817_70	Height	2.000000e-18
GCST000892_1	Total ventricular volume (Alzheimer’s disease interaction)	2.000000e-06
GCST001956_44	Height	2.000000e-08
GCST003542_12	Night sleep phenotypes	1.000000e-06
GCST007822_1	Facial attractiveness (male raters)	2.000000e-08
GCST007843_3	Rheumatoid arthritis	1.000000e-09
GCST008163_388	Height	2.000000e-06
GCST008839_226	Height	5.000000e-08
GCST008839_513	Height	2.000000e-28
GCST008839_521	Height	1.000000e-09
GCST010697_38	Cortical surface area (min-P)	3.000000e-41
GCST010698_1	Subcortical volume (min-P)	4.000000e-08
GCST010699_86	Brain morphology (min-P)	6.000000e-14
GCST010700_70	Cortical thickness (MOSTest)	8.000000e-09
GCST010701_81	Cortical surface area (MOSTest)	5.000000e-09
GCST010702_53	Subcortical volume (MOSTest)	2.000000e-12
GCST010703_207	Brain morphology (MOSTest)	2.000000e-11
GCST011011_7	Youthful appearance (self-reported)	7.000000e-16
GCST011616_43	Cortical volume	3.000000e-10
GCST011743_31	HDL cholesterol levels in HIV infection	3.000000e-06
GCST90020029_799	Waist circumference adjusted for body mass index	2.000000e-08

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0009892	facial attractiveness measurement
EFO:0004346	neuroimaging measurement
EFO:0004840	cortical thickness
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0007789	BMI-adjusted waist circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

66 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tretinoin	affects cotreatment, decreases expression, increases expression	4
methylmercuric chloride	increases expression	3
trichostatin A	affects cotreatment, decreases expression	3
sodium arsenite	decreases expression, affects cotreatment, increases abundance	2
Panobinostat	affects cotreatment, decreases expression	2
Progesterone	increases expression	2
Valproic Acid	affects expression, increases expression	2
Aflatoxin B1	affects expression, increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	increases phosphorylation	1
TL8-506	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, decreases methylation	1
methylselenic acid	increases expression	1
arsenite	affects binding, increases reaction	1
cobaltous chloride	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
coumarin	increases phosphorylation	1
S-(1,2-dichlorovinyl)cysteine	decreases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
cylindrospermopsin	increases expression	1
corosolic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
dorsomorphin	increases expression, affects cotreatment, decreases expression	1
PCI 5002	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	affects cotreatment, decreases expression	1
Fulvestrant	decreases methylation, affects cotreatment	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.